Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study

Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial

(2018) Gilles R. Dagenais et al.   Journal of the American Heart Association

Combined use of polypill components in patients with type 2 diabetes mellitus

(2018) Vivi E Janssen et al.   European Journal of Preventive Cardiology

Role of the polypill for secondary prevention in ischaemic heart disease

(2017) José M Castellano et al.   European Journal of Preventive Cardiology

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

(2016) Eva M. Lonn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

(2016) Salim Yusuf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease

(2016) Salim Yusuf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Statin Safety in Chinese: A Population-Based Study of Older Adults

(2016) Daniel Q. Li et al.   PLoS One

Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States

(2015) Bruce K. Birmingham et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

(2015) Daniel I Swerdlow et al.   LANCET

Guidelines for the Primary Prevention of Stroke

(2014) James F. Meschia et al.   STROKE

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

(2013) et al.   EUROPEAN HEART JOURNAL

An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill (“Polypill”) in People with Raised Cardiovascular Risk

(2011)   PLoS One

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial

(2009)   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE